

Investor Day 2024 Value Creation: The Next Wave

November 8, 2024

Value Creation: The Next Wave

| Topic | Speaker |
|------------------------------|--|
| Welcome and Introduction | Jeff Geyer |
| Sustaining Profitable Growth | Joe Zubretsky |
| Compelling Financial Profile | Mark Keim |
| Q&A | Joe Zubretsky Mark Keim Jim Woys |



Cautionary Statement

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This presentation and the accompanying oral remarks include forward-looking statements regarding, without limitation, the Company's growth strategy and long-term growth rate, embedded earnings and their realization, market share goals, the sustaining of our profit margins, Medicaid redeterminations or reverifications and the management of our medical costs, future RFPs and our RFP success rate, M&A activity and the sustaining of our acquisitions pipeline, Medicaid rates and Medicaid carve-ins and carve-outs, our 2024 guidance, our 2025 outlook, our long-term financial goals and projected earnings and EPS growth, and the Company's general business plans. The Company intends such forward-looking statements to be covered by the safe harbor provisions for forward looking statements contained in the Private Securities Litigation Reform Act of 1995. Readers and listeners are cautioned not to place undue reliance on any forward-looking statements as forward-looking statements are not guarantees of future performance, and the Company's actual results may differ materially due to numerous known and unknown risks and uncertainties. Those risks and uncertainties are discussed under Item 1A in the section entitled "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2023, and also in the Company's quarterly reports, current reports, and other reports and filings with the Securities and Exchange Commission, or SEC. These reports can be accessed under the investor relations tab of the Company's website or on the SEC's website at www.sec.gov. All forward looking statements in this presentation represent management's judgment as of November 8, 2024, and, except as otherwise required by law, the Company disclaims any obligation to update any forward-looking statements to conform the statement to actual results or changes in its expectations.





Sustaining Profitable Growth

Joe Zubretsky
President and Chief Executive Officer

Our Historical Performance

Our track record sets the foundation for our long-terms targets

| What We Delivered (2019 to 2024G) | What We Will Do (2024G to 2027) |
|-----------------------------------|---|
| - 19% Premium CAGR | - 11% - 13% Premium CAGR |
| -\$6B from current footprint | - \$5B from current footprint |
| - \$7B from strategic initiatives | - \$4B-\$7B from strategic initiatives |
| -\$9B from acquisitions | - \$5B from acquisitions |
| - 4.7% pre-tax margin | - 4% - 5% pre-tax margin |
| - 15% EPS CAGR | - 13% - 15% EPS CAGR |
| | |
| | - 19% Premium CAGR - \$6B from current footprint - \$7B from strategic initiatives - \$9B from acquisitions - 4.7% pre-tax margin |



Performance Outlook

Our strategy will produce sustainable, profitable growth and industry leading margins

| Premium Revenue Growth | Pretax Margin | Adjusted EPS Growth |
|------------------------|--------------------|---------------------|
| 11% - 13% | 4% - 5% | 13% - 15% |
| 7% - 9% | 87.5% - 88.5% | 11% - 13% |
| Organic Growth | Medical Cost Ratio | Earnings Growth |
| ~4% | < 7% | ~2% |
| Acquisitions | G&A Ratio | Share Repurchases |



Sustaining Profitable Growth





Value Creating Franchise

The Molina Franchise



A leading pure-play, government-sponsored managed care franchise with depth, breadth, and scale

500

229

1

128 Ranking

\$38B Premium Revenue 2024G


5.7MMembers
YE 2024


21 States 2024 **3**Products
Medicaid, Medicare
and Marketplace

Costing Sales

Diversified and Balanced Portfolio

Geographically diversified portfolio of complementary product segments








Castles Sales Falles

Portfolio Synergies

Synergistic product segments provide member continuity and leverage common capabilities






Long-Term Value Creation



A proven track record of industry-leading profitable growth and shareholder value creation








Premium Revenue Growth

19% trailing five-year CAGR was well balanced between organic growth and M&A, more than doubling the size of the Company while maintaining industry leading margins





Organic Premium Revenue Growth

Total organic premium growth of 11% was above the high end of our long-term range led by the Medicaid flagship

| | Prior Long-term Target | 2019 - 2024G Achieved |
|----------------|---------------------------|--------------------------|
| Medicaid | 8% - 10% | 12% |
| Medicare | 11% - 13% | 5% |
| Marketplace | 5% - 8% | 11% |
| Weighted Total | 8% - 10% | 11% |

Parameter.

RFP Wins and Accretive Acquisitions

A successful history of retaining existing contracts and delivering new store growth through RFP wins and accretive acquisitions









Per care line

Adjusted EPS Growth

Adjusted EPS growth is achieved through current footprint and new store embedded earnings. \$6.00 remains for 2025 through 2027.









Environment

Government Managed Care Market

Addressable markets exceed \$750 billion in annual spend with attractive, profitable growth opportunities








Environment

Molina Market Share Profile

Market shares across all segments are large enough for scale and relevancy but allow for substantial growth opportunity



Environment

Political and Regulatory Environment

We focus on the possible policy changes and what it would take to make them in any political scenario

| Policies in Focus | | | |
|-------------------|--|--|--|
| Medicaid | Work requirements Dual-eligible integration Medicaid expansion | | |
| Medicare | Risk adjustment & Stars Dual-eligible integration Entitlement reform | | |
| Marketplace | Expiration of enhanced subsidies Affordable Care Act repeal Eligibility & enrollment | | |


| | Paths to Modify Policies | | |
|---|---|--|--|
| 1 | State-level legislation | | |
| 2 | Federal legislation & Budget Reconciliation | | |
| 3 | Executive Orders | | |
| 4 | Regulatory bodies and rulings | | |
| 5 | Judicial rulings | | |

Highly Attractive Business Mix

The current environment creates a very favorable outlook for all Molina segments

Medicaid Environment

- Actuarially sound rates
- Expansion of entitlement programs
- Growth in low-wage service economy
- Growing penetration of managed Medicaid programs



Medicare Duals Environment

- Duals growth projected to exceed traditional Medicare
- Shift towards integration of Medicare & Medicaid products

Marketplace Environment

- Rational pricing environment with stable risk pools
- Significant opportunity if subsidies are extended

The Growth Model Medicaid / Medicare / Marketplace / Accretive M&A



Long-Term Premium Revenue Growth Targets

Strong, balanced organic growth complemented by a disciplined acquisition strategy

Organic Growth

| Medicaid | 7% - 9% |
|----------------|---------------------|
| Medicare | 12% - 14% |
| Marketplace | 5% with Optionality |
| Weighted Total | 7% - 9% |



Contract of the second


The Growth Model

The growth model is well-balanced between organic drivers and accretive M&A




2027 Premium Revenue Target

Premium revenue growth target of 11% - 13% is well-balanced and maintains the trajectory to achieve the previous outlook of \$46 billion in 2026



2027 Premium Revenue Target

Of the \$9 to \$12 billion of premium revenue growth from strategic initiatives and M&A, approximately 50% has already been secured







Medical Agoda

Medicaid Long-Term Growth

Long-term growth target of 7% - 9% is driven by the current footprint, in-flight initiatives, and projected strategic initiatives



Medicale de

Sizing the New State RFP Opportunity

New state RFPs yield \$30 billion of revenue opportunity by 2027 with \$50 billion in active procurement cycle



Molina's Proven RFP Formula

State of the other o

Our RFP approach is built on execution of proven business development capabilities and a track record of operational excellence

| | Target Selection Criteria | | Formula |
|---|---|---|-------------------------------|
| 1 | Size and duration of contract | 1 | Effective gro two years be |
| 2 | Strength of incumbents | 2 | Strong propo |
| 3 | Number of awardees | | |
| 4 | Access to high-quality low-cost network | 3 | Demonstrate success and |
| 5 | Rational rate environment | 4 | Clinical and |
| | | 4 | |

| Formula Components | | | |
|--------------------|---|--|--|
| 1 | Effective ground game that starts two years before RFP | | |
| 2 | Strong proposal writing team | | |
| 3 | Demonstrated track record of program success and leading capabilities | | |
| 4 | Clinical and operational innovation | | |

Ste Challe And Challe

Increase Market Share

Focus on fundamental operating tactics will drive significant market share gain opportunity



Stedicale de


Pursue Carve-in Opportunities

Maximize carve-in opportunities as states increasingly leverage managed care's capabilities






MOLINA



Season the seasons

Medicare Long-Term Growth

Long-term growth target of 12% - 14% is driven by the current footprint, in-flight initiatives, and projected strategic initiatives






Molina Strategic Position

Our Medicare segment is largely comprised of Duals products with significant overlap of Medicaid plans in 16 states as we leverage our Medicaid footprint

| Product | States | 2024G Members (K) | 2024G Premium (B) |
|----------------|--------|-------------------------|----------------------|
| ММР | 5 | 50 | \$1.8 |
| DSNP/HIDE/FIDE | 15 | 120 | \$3.0 |
| Total Duals | 16 | 170 | \$4.8 |
| Non-Duals | 15 | 80 | \$0.8 |
| Total | 16 | 250 | \$5.6 |





Made No day

Increasing Duals Alignment

CMS and state policies are increasingly focused on alignment of Medicaid and Medicare products. Both scenarios are projected to have attractive high-growth markets.

CMS Guidance

- The 2025 Final Rule encourages increased integration of Medicare and Medicaid
- The new rule also delegates policy and implementation decisions to individual states

| | Scenario 1 | Scenario 2 | | |
|-------------------------------|---|---|--|--|
| State Policy | Any D-SNP MCO can enroll Duals | Only MCOs with Medicaid and Medicare can enroll Duals | | |
| Implications for Molina | No Change Operating environment remains largely unchanged | Increased Opportunity MOH Medicaid footprint creates D-SNP market share opportunity | | |



State of the Other

Maximize MMP Conversion into HIDE / FIDE

We have begun to transition our MMP members into HIDE or FIDE product with early success in Michigan and Ohio



Product Dynamics & Status

- Successfully procured 2 states (MI & OH)
- 1 remaining state-wide procurement where Molina carries strength of incumbency
- 2 remaining states will transition existing programs
- Molina partnering with states to seamlessly crosswalk members to integrated products

| States | MI | ОН | IL | TX | SC | Total MMP |
|---------------|-------|-------|---------|-------|-------|-----------|
| Procured | 1 | 1 | Pending | N/A | N/A | |
| Premium (\$B) | \$0.3 | \$0.7 | \$0.4 | \$0.3 | \$0.1 | \$1.8B |




He de de de

Increase Duals Market Share

Focus on fundamental operating tactics, product design, distribution expansion and pricing discipline will drive significant market share opportunity





STORTH NO OR

Marketplace Long-Term Growth


Long-term growth target of ~5% is driven by the current footprint with optionality from projected initiatives





Strong Market Growth

Several market dynamics have driven substantial growth



Market Dynamics

- Enhanced subsidies were extended through 2025
- Year-round Special Enrollment Period for under 150% FPL was made permanent
- Members transitioned from Medicaid throughout Redetermination
- Return to rational pricing environment and improved margins resulted in greater competition

Market Outlook

Continued organic growth expected to offset disenrollments from the potential expiration of enhanced subsidies



Subsidy Dynamics


- Outlook assumes ~20% of enrollees could exit the market if enhanced subsidies expire
- Additional buy-downs to Bronze plans vary based on geography and member mix
- Significant opportunity for Molina growth outlook if enhanced subsides are extended



Stant to Add to

Increase Market Share

Focus on fundamental operating tactics, product design, distribution expansion and pricing discipline will drive significant market share opportunity





Accretive M&A

ACCOMPAGE

M&A Platform

M&A is a key element of the long-term premium growth targets

- Ample excess cash flow internally funds acquisitions
- Previously announced purchase prices are highly capital efficient

We buy long-dated, stable revenue streams

Underperforming properties yield accretion from sweat equity

M&A generally as accretive as new procurement economics

Expert integration teams ensure accretion targets are achieved



ACCOMPAGE

M&A Pipeline

The acquisition pipeline remains robust with many remaining opportunities




- Numerous acquisition opportunities are actionable
 - 2 Turnarounds provide attractive economics
- Capitated risk, not services or vertical integration
- 2027 requires \$5 billion of acquired revenue. \$1.4 billion has been announced.



M&A Track Record

Seven completed transactions sequenced for manageable integration and one transaction pending










Recent transactions were purchased at capital efficient prices and yield accretion from sweat equity

7 ~\$9 Billion ~\$2.3B Revenue Capital Transactions Acquired completed Deployed ~5.5x < 25% ~\$4.00 Average Purchase Average Embedded Earnings EV / EBITDA Multiple as % of Premium Harvested < 4 Years ~30% ~\$2.65 Current Average Return on Payback Period Embedded Earnings Equity



Operating Excellence

It is not only what we do but how we do it that is important our continued success


Focus on **Fundamentals**

The Molina **Playbook**

Serving All Constituencies

The Team





Performance Outlook

Our strategy will produce sustainable, profitable growth and industry leading margins

| Premium Revenue Growth | Pretax Margin | Adjusted EPS Growth |
|------------------------|--------------------|---------------------|
| 11% - 13% | 4% - 5% | 13% - 15% |
| 7% - 9% | 87.5% - 88.5% | 11% - 13% |
| Organic Growth | Medical Cost Ratio | Earnings Growth |
| ~4% | < 7% | ~2% |
| Acquisitions | G&A Ratio | Share Repurchases |



Calloot o

Investment Thesis

Shareholder value is driven by strong growth, sustained margins and disciplined capital management





Compelling Financial Profile

Mark Keim Chief Financial Officer

Compelling Financial Profile




Molina Margin Mechanics

Industry-leading Medicaid MCRs

Molina consistently outperforms peers due to disciplined medical cost management

Medical Cost Management

- Rates are established at the market level...each MCO gets the same rates
- Corridors are established at the market level...
 each MCO is subject to the same corridors
- Members are generally evenly distributed among 3-5 MCO's... each MCO has similar acuity profiles
- Disciplined management of medical costs is the only differentiator



MOLINA

Source: S&P Capital IQ and statutory flings

Medical Cost Management

Numerous capabilities drive medical cost efficiencies with focus on high-acuity populations



Operating Focus

- State-of-the-art medical economics platform
- Utilization management
- High-acuity care management
- FFS and value-based contracting
- Payment integrity
- Centers of Excellence for behavioral health, pharmacy, and LTSS




Medicaid Margin Sustainability

Rate setting on total market population cost base provides Molina opportunity to continually drive MCR outperformance

Market Risk Pool

- Cost trend included in rates as CMS requires rate setting to be actuarially sound
- State actuarial processes set rates on total program population, not individual MCO's
- Molina's sustainable, best in class margins driven by continually outperforming total state populations
- All plans must satisfy quality requirements



Example Market MCRs

Market Share

Plan 2

25%

Plan 3

25%

Plan 4

25%


Total Population

Plan 1 25%



Risk Corridors

Medicaid risk corridor positions are a result of margin outperformance and help mitigate potential inflections in medical cost trends



Risk Corridor Dynamics

- Molina averaged ~200 basis points of risk corridor expense/protection over the past few years
- In 2024, risk corridors absorbed higher medical costs due to Redetermination acuity shifts
- We expect to use ~100 basis points of risk corridor buffer in 2024 as rates have not matched trend
- Historical risk corridor protection level is expected to be replenished with the new rate cycle



G&A Expense Management

Continued expense management and operating leverage drive lower G&A ratio while building capabilities for continued outperformance

+

Expense Management

- Fixed cost leverage
- Productivity gains
- Outsourcing commoditized functions
- Automation, digitization and AI
- No frills environment

Leveraging the Base



Building Capabilities

- Artificial intelligence
- Member and provider experience
- New business development
- M&A integration
- Medical economics and data analytics
- Population health







2024 Guidance


Full year 2024 guidance is reaffirmed

| | FY 2023 | FY 2024 | Suidance |
|------------------|---------|-----------|-----------|
| | Actual | Initial | Current |
| Premium Revenue | \$32.5B | ~\$38B | ~\$38B |
| Adjusted EPS | \$20.88 | ≥ \$23.50 | ≥ \$23.50 |
| MCR % | 88.1% | 88.2% | 88.7% |
| Medicaid | 88.7% | 89.0% | 90.0% |
| Medicare | 90.7% | 88.0% | 88.3% |
| Marketplace | 75.3% | 78.0% | 74.0% |
| G&A % | 7.2% | 7.0% | 6.8% |
| Pre-tax Margin % | 4.8% | 4.6% | 4.6% |
| Share Count | 58.1M | 58.1M | 57.9M |



Medicaid MCR: 2Q24 to 3Q24

Adjusting for CA retro items, the Medicaid MCR decreased 10 basis points driven by new store improvements and rates and risk corridors offsetting higher trend




MOLINA

Gulden Co

Medicaid MCR: 3Q24 to 4Q24


Adjusting for CA retro items, we expect the Medicaid MCR to decrease 100 basis points driven by new store improvements, known rates, and risk corridors offsetting moderating trend



Guttano

Medicaid MCR: Full Year Guidance


Increased MCR guidance driven by higher trend partially offset by rates and risk corridors




Guldano

Medicaid Medical Cost Trend

Full year 2024 trend is now expected to be 6% and reflects equal contribution from the acuity shift and core trend








Guttanga

2024 EPS Guidance

We reaffirm guidance of at least \$23.50 with Marketplace, G&A ratio, and NII offsetting higher MCR's in Medicaid and Medicare







Medicaid Rate Environment

The rate cycle is well-timed with 55% of premium renewing on January 1st

Core Rates

- Known on-cycle rates were 4.5% in 3Q24 and 9% in 4Q24
- Off-cycle rates were 1.5% in 3Q24
- 55% of revenues reset January 1st
- Known January rates are in draft form
- We continue to expect off-cycle rate adjustments as data develops

Premium Rate Profile

| Fiscal Year Start | Q1 | Q2 | Q3 | Q4 | FY2025 |
|--------------------|------|------|------|------|--------|
| Number of States | 10 | 1 | 6 | 3 | 21 |
| % of Total Premium | ~55% | ~10% | ~25% | ~10% | 100% |




2025 Premium Revenue Outlook



Known building blocks provide current outlook of ~8% premium revenue growth

In \$ Billions



MOLINA

Realization of Embedded Earnings


Cartilate Park

Embedded earnings of \$6.00 remain balanced between acquisitions and new contracts, with less than half expected to be realized in 2025

| | g. | Realization | | | | |
|---------------|---------------|-------------|---------------|--|--|--|
| Driver | 2024 Year End | 2025 | 2026 and 2027 | | | |
| Acquisitions | \$2.65 | (\$0.90) | (\$1.75) | | | |
| New Contracts | \$3.35 | (\$1.10) | (\$2.25) | | | |
| Total | \$6.00 | (\$2.00) | (\$4.00) | | | |

2025 Medicaid MCR Components

Achieving the high-end of the long-term MCR target range requires 20 basis points of benefit off 2H 2024 guidance from the combination of rates, trend, and risk corridors




MOLINA

2025 Adjusted EPS Building Blocks

Children of the Children

Medicaid margin is the largest driver of our outlook for current footprint and relies heavily on rates and trends









Strong Capital Foundation

Strong balance sheet provides foundation for stability and growth

| 3Q 2024 Credit Stats | | Reserve Streng | gth |
|---------------------------|---------|------------------------|---------|
| Net Debt to EBITDA Ratio | 1.4x | Reserves at 9/30/24 | \$4.7B |
| Net Debt / Capitalization | ~35% | | |
| Revolver Capacity | \$1.25B | Days in Claims Payable | 48 Days |
| | | | |

| INCCUITING FAICHT CASH FIOW | Recurring | Parent | Cash | Flow |
|-----------------------------|-----------|--------|------|------|
|-----------------------------|-----------|--------|------|------|

| 2024 Dividends to Parent | >\$950M |
|--------------------------|---------|
|--------------------------|---------|

Dividend to Net Income Conversion 80% - 100%

| Acquisition Capacity as of | 4Q 2025 |
|----------------------------------|---------|
| Parent Company Cash | ~\$500M |
| Debt Capacity | ~\$4.0B |
| Total Deployable Capital 4Q 2025 | ~\$4.5B |



Foundation

Capital Deployment Discipline

Capital deployment is prioritized to opportunities with the highest returns


| | | EPS Accretion | Long-Term Target Capital Allocation |
|---------------------------|--|----------------------|--|
| Re-invest in Business | Organic growth is the highest priority Most efficient use of capital to grow All lines of business are high growth | Y Y Y | ~25% |
| Accretive Acquisitions | Robust pipeline Disciplined approach Strategic fit and operational synergies | ~ | ~50% |
| Return to Shareholders | - Share repurchases | | ~25% |

Long-Term Financial Targets

Long-Term Targets

Molina has a clear formula to deliver organic premium growth and sustainable MCR to achieve pretax margins


| | Organic Premium Growth | Medical Cost Ratio |
|--|------------------------------|--------------------------|
| Medicaid | 7% - 9% | 88% - 89% |
| Medicare | 12% - 14% | 87% - 88% |
| Marketplace | 5% with Optionality | 78% - 80% |
| Weighted Total At current portfolio mix | 7% - 9% | 87.5% - 88.5% |





2027 Premium Revenue Target


Of the \$9 to \$12 billion of premium revenue growth from strategic initiatives and M&A, approximately 50% has already been secured





2027 Strategic Initiative Opportunity

2027 premium target requires realization of ~20% of total identified strategic initiatives, a conservative view



Long-Term EPS Growth

Strong revenue and earnings growth is enhanced by operating leverage and share repurchases

| Premium Revenue Growth | 11% - 13% |
|---------------------------------------|-----------|
| Hedge to Margins / Operating Leverage | 0% - 1% |
| Net Income Growth | 11% - 13% |
| Share Repurchases | ~2% |
| EPS Growth | 13% - 15% |

...while continually refreshing embedded earnings to support forward growth



Performance Outlook

Our strategy will produce sustainable, profitable growth and industry leading margins

| Premium Revenue Growth | Pretax Margin | Adjusted EPS Growth |
|------------------------|--------------------|---------------------|
| 11% - 13% | 4% - 5% | 13% - 15% |
| 7% - 9% | 87.5% - 88.5% | 11% - 13% |
| Organic Growth | Medical Cost Ratio | Earnings Growth |
| ~4% | < 7% | ~2% |
| Acquisitions | G&A Ratio | Share Repurchases |



The Hallon

Investment Thesis

Shareholder value is driven by strong growth, sustained margins and disciplined capital management





Q&A

Reconciliation of Non-GAAP Financial Measures

Adjustments represent additions and deductions to GAAP net income as indicated in the table below, which include the non-cash impact of amortization of acquired intangible assets, acquisition-related expenses, and the impact of certain expenses and other items that management believes are not indicative of longer-term business trends and operations. Managements opinions on business trends and operations can change, so the adjustments included in the table will not be consistent from period to period.

| 20 | 2020 2021 | | 21 | 20 | 22 | 2023 | | 2024G(1) | |
|-----|-----------|--|---|--|---|--|---|--|---|
| s | 11.23 | s | 11.25 | S | 13.55 | \$ | 18.77 | s | 21.59 |
| 25 | | | 2,6 | | | | - | | |
| | 0.26 | | 0.83 | | 1.32 | | 1.47 | | 1.43 |
| | 0.37 | | 1.59 | | 0.83 | | 0.12 | | 0.86 |
| | | | | | 3.56 | | | | |
| | 0.26 | | 0.43 | | | | | | |
| | (2.14) | | | | - | | 10.7 | | - |
| 4.5 | 0.51 | | 0.16 | | | 0.1 | 1.17 | i. | 0.27 |
| | (0.74) | | 3.01 | | 5.71 | | 2.76 | | 2.56 |
| | 0.18 | | (0.72) | | (1.34) | | (0.65) | | (0.65) |
| 37 | (0.56) | | 2.29 | | 4.37 | 9 | 2.11 | | 1.91 |
| S | 10.67 | S | 13.54 | s | 17.92 | S | 20.88 | S | 23.50 |
| | \$ | \$ 11.23 0.26 0.37 0.26 (2.14) 0.51 (0.74) 0.18 (0.56) | \$ 11.23 \$ 0.26 0.37 0.26 (2.14) 0.51 (0.74) 0.18 (0.56) | \$ 11.23 \$ 11.25 0.26 0.83 0.37 1.59 0.26 0.43 (2.14) - 0.51 0.16 (0.74) 3.01 0.18 (0.72) (0.56) 2.29 | \$ 11.23 \$ 11.25 \$ 0.26 0.83 0.37 1.59 0.26 0.43 (2.14) 0.51 0.16 (0.74) 3.01 0.18 (0.72) (0.56) 2.29 | \$ 11.23 \$ 11.25 \$ 13.55 0.26 0.83 1.32 0.37 1.59 0.83 3.56 0.26 0.43 (2.14) 0.51 0.16 - (0.74) 3.01 5.71 0.18 (0.72) (1.34) (0.56) 2.29 4.37 | \$ 11.23 \$ 11.25 \$ 13.55 \$ 0.26 0.83 1.32 0.37 1.59 0.83 3.56 0.26 0.43 (2.14) 0.51 0.16 (0.74) 3.01 5.71 0.18 (0.72) (1.34) (0.56) 2.29 4.37 | \$ 11.23 \$ 11.25 \$ 13.55 \$ 18.77 0.26 0.83 1.32 1.47 0.37 1.59 0.83 0.12 3.56 0.26 0.43 (2.14) 0.51 0.16 - 1.17 (0.74) 3.01 5.71 2.76 0.18 (0.72) (1.34) (0.65) (0.56) 2.29 4.37 2.11 | \$ 11.23 \$ 11.25 \$ 13.55 \$ 18.77 \$ 0.26 0.83 1.32 1.47 0.37 1.59 0.83 0.12 3.56 0.26 0.43 (2.14) 0.51 0.16 - 1.17 (0.74) 3.01 5.71 2.76 0.18 (0.72) (1.34) (0.65) (0.56) 2.29 4.37 2.11 |

^{(1) 2024} Guidance as of October 23, 2024

^{(3) 2020} includes charitable contribution, premium deficiency reserves, and restructuring costs. 2021 includes change in premium deficiency reserves, loss on sale of property, and restructuring costs. 2022 includes gain on lease termination and disposal of fixed assets. 2023 includes a credit loss on 2022 Marketplace risk adjustment receivables due to the insolvency of an issuer in the Texas pool. 2024 includes litigation and one-time termination benefits.



⁽²⁾ Resulting from the Company's plan to reduce its leased real estate footprint